Oncología Traslacional

ONCTRAS

Foto de Oncología Traslacional

Foto de Antonio

Antonio
Llombart Cussac

Antonio Llombart Cussac-rekin lankidetzan egindako argitalpenak (6)

2021

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

2019

Corrigendum: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis (Annals of Oncology (2012) 23 (1130-1137) DOI: 10.1093/annonc/mdr432)
Annals of Oncology

2017

18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

2012

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137
Progress against solid tumors in danger: The metastatic breast cancer example
Journal of Clinical Oncology